Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Newly Diagnosed Glioblastoma: early-phase trial registry
4 of 5 indexed Newly Diagnosed Glioblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Newly Diagnosed Glioblastoma: 5 US clinical trials tracked, 4 recruiting.
Newly Diagnosed Glioblastoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Black Diamond Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition newly-diagnosed-glioblastoma
OPEN 4 | RECR 80% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Newly Diagnosed Glioblastoma lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Newly Diagnosed Glioblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Newly Diagnosed Glioblastoma is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Newly Diagnosed Glioblastoma research.
Black Diamond Therapeutics accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Newly Diagnosed Glioblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 68 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Newly Diagnosed Glioblastoma research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics
NCT07326566
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Duke University
NCT06816927
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Northwestern University
NCT05864534
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
Swedish Medical Center
NCT05380349
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
University of Michigan Rogel Cancer Center
NCT04477200
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Newly Diagnosed Glioblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Newly Diagnosed Glioblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Newly Diagnosed Glioblastoma page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Newly Diagnosed Glioblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Black Diamond Therapeutics sponsors the most Newly Diagnosed Glioblastoma trials on record, review their full trial history before evaluating a specific study. See Black Diamond Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Newly Diagnosed Glioblastoma condition card totals 5 registered trials; most-linked intervention Radiation Therapy; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.